Clene Inc. (CLNN) NASDAQ
5.57
+0.24(+4.50%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
5.57
+0.24(+4.50%)
Currency In USD
| Previous Close | 5.33 |
| Open | 5.34 |
| Day High | 5.72 |
| Day Low | 5.25 |
| 52-Week High | 13.5 |
| 52-Week Low | 3.25 |
| Volume | 103,374 |
| Average Volume | 493,525 |
| Market Cap | 57.41M |
| PE | -1.71 |
| EPS | -3.25 |
| Moving Average 50 Days | 6.27 |
| Moving Average 200 Days | 6.55 |
| Change | 0.24 |
Clene Issues Stockholder Letter Highlighting Upcoming CNM-Au8® 2026 Catalysts
GlobeNewswire Inc.
Feb 24, 2026 1:00 PM GMT
Operating capital runway sufficient into the fourth quarter of 2026 In-person Type C FDA meeting scheduled by end of the first quarter of 2026 to discuss the latest CNM-Au8 data submitted in late 2025Anticipated submission of a New Drug Application (
Clene Announces Additional CNM-Au8 Biomarker Data Supporting Potential NDA Filing for Upcoming In-Person FDA Meeting
GlobeNewswire Inc.
Jan 12, 2026 1:30 PM GMT
The FDA has granted an in-person Type C meeting during the first quarter of 2026 New independent analyses across large observational ALS cohorts demonstrate that modest (~10%) NfL reductions are significantly associated with lower mortality risk, sup
Clene Announces Registered Direct Offering of Over $28 Million
GlobeNewswire Inc.
Jan 09, 2026 1:30 PM GMT
Oversubscribed registered direct offering priced above market to new, existing and insider investors, including Boxer Capital Management, Coastlands Capital, and Vivo CapitalInitial financing tranche of over $6 million, which we expect will provide c